Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (Pediatric MATCH)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Armatti, Julie M; Doyle, Katherine M; Dubberly, Paige D; Parker, Melanie
Trial Phone: 321.841.5357 ; 321-843-5284 ; 3218412008 ; 321-841-7561 ; 321-843-1036
-
IRB No: APEC1621K
Protocol Abbrev: APEC1621K
Principal Investigator: Amy A. Smith, MD
Phase: Drug: Phase II
Age Group: Adult;Pediatric
Secondary Protocol No: APEC1621K
Treatment: Drug: Ivosidenib
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT04195555
-
Objective
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with AG-120 (ivosidenib) with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in the IDH1 pathway.
-
Key Eligibility
Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
